A Post Marketing Surveillance on Lutathera (Lutetium (177Lu) Oxodotreotide, 177Lu-DOTA0-Tyr3-Octreotate) in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) in Korea
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 09 Aug 2024 Status changed from active, no longer recruiting to completed.
- 15 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2023 Planned End Date changed from 30 Jun 2023 to 8 Jul 2024.